Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 162, Issue 1, Pages 74-86
Publisher
Wiley
Online
2013-04-25
DOI
10.1111/bjh.12354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
- (2012) Esther Natalie Oliva et al. ANNALS OF HEMATOLOGY
- Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
- (2012) F. Damm et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Incidence of 17p deletions andTP53mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion
- (2012) Amel Sebaa et al. GENES CHROMOSOMES & CANCER
- Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome
- (2012) C. P. Venner et al. HAEMATOLOGICA
- Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited
- (2012) Andres Jerez et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients
- (2012) N Douet-Guilbert et al. LEUKEMIA
- Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q− MDS (IPSS low and intermediate-1)
- (2012) Anna Jonasova et al. LEUKEMIA RESEARCH
- Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
- (2012) S Wei et al. ONCOGENE
- Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients
- (2011) Mrinal M. Patnaik et al. AMERICAN JOURNAL OF HEMATOLOGY
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- (2011) P. Fenaux et al. BLOOD
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
- (2011) R. V. Tiu et al. BLOOD
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide
- (2011) G Göhring et al. LEUKEMIA
- Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience
- (2011) Fabien Le Bras et al. LEUKEMIA RESEARCH
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
- (2010) Katharina Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)
- (2010) A Pardanani et al. LEUKEMIA
- Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q)
- (2010) C Chen et al. LEUKEMIA
- WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
- (2010) M M Patnaik et al. LEUKEMIA
- Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
- (2010) M Mallo et al. LEUKEMIA
- Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies
- (2009) Jaroslaw P. Maciejewski et al. BRITISH JOURNAL OF HAEMATOLOGY
- Circos: An information aesthetic for comparative genomics
- (2009) M. Krzywinski et al. GENOME RESEARCH
- Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
- (2009) M. Jadersten et al. HAEMATOLOGICA
- Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies
- (2009) Hideki Makishima et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
- (2009) N Carbuccia et al. LEUKEMIA
- Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics
- (2009) S Heinrichs et al. LEUKEMIA
- Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype
- (2009) Daniel T Starczynowski et al. NATURE MEDICINE
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytogenetic features in myelodysplastic syndromes
- (2008) Detlef Haase ANNALS OF HEMATOLOGY
- Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays
- (2008) L. Wang et al. HAEMATOLOGICA
- Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
- (2008) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
- (2008) Benjamin L. Ebert et al. NATURE
- An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
- (2008) Benjamin L Ebert et al. PLOS MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started